Nkarta gains on positive data from lymphatic cancer therapy trial

Nkarta

05/12/2022 12:38

** Shares of cell therapy developer Nkarta Inc  NKTX.O  rise
11.6% to $9.6 before the bell 
    ** Co reports updated positive data from early-stage dose
escalation trial of NKX019 as a monotherapy to treat non-Hodgkin
lymphoma (NHL) patients
    ** NHL is a cancer type that starts in lymphatic system
    ** Co says seven of 10 patients treated at the higher dose
levels showed a complete response rate of 70% 
    ** NKX019 continues to show single-agent activity,
preliminary durability and an encouraging safety profile -
Nkarta 
    ** Co plans to provide updates from the NKX019 program,
including data from its other dose expansion cohorts, in 2023 
    ** YTD stock down ~44%, as of last close
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))